Precision Medicine in Oncology®

The Centers for Medicare & Medicaid Services has expanded coverage of laboratory diagnostic tests that utilize next-generation sequencing that have been approved or cleared by the FDA for use in patients with germline ovarian or breast cancers.

Recent studies have demonstrated that somatic mutations of ATM denote greater response to radiation therapy and that gene patterns may help predict the timing of recurrence following radiation.

Francisco J. Esteva, MD, PhD, discusses how the use of precision medicine has helped improve the treatment of patients with breast cancer.

Heather H. Cheng, MD, PhD, discusses considerations for molecular testing in prostate cancer.

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.